Teva Pharmaceutical Industries Ltd (TEVA) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.038x

Based on the latest financial reports, Teva Pharmaceutical Industries Ltd (TEVA) has a cash flow conversion efficiency ratio of 0.038x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA313.17 Million ≈ $839.59K USD) by net assets (ILA8.31 Billion ≈ $22.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TEVA cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Teva Pharmaceutical Industries Ltd - Cash Flow Conversion Efficiency Trend (1991–2025)

This chart illustrates how Teva Pharmaceutical Industries Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Teva Pharmaceutical Industries Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Teva Pharmaceutical Industries Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
PT Daya Intiguna Yasa Tbk
JK:MDIY
0.236x
IDT Corporation
NYSE:IDT
0.104x
Wealthfront Corporation Common Stock
NASDAQ:WLTH
0.037x
Adriatic Metals Plc
F:3FN
-0.035x
Manchester United Ltd
NYSE:MANU
0.005x
Growthpoint Properties Australia
AU:GOZ
0.031x
Hangjin Technology Co Ltd
SHE:000818
0.173x
BioGaia AB (publ)
ST:BIOG-B
0.050x

Annual Cash Flow Conversion Efficiency for Teva Pharmaceutical Industries Ltd (1991–2025)

The table below shows the annual cash flow conversion efficiency of Teva Pharmaceutical Industries Ltd from 1991 to 2025. For the full company profile with market capitalisation and key ratios, see TEVA market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ILA7.92 Billion
≈ $21.22 Million
ILA3.10 Billion
≈ $8.31 Million
0.392x +79.59%
2024-12-31 ILA5.72 Billion
≈ $15.34 Million
ILA1.25 Billion
≈ $3.34 Million
0.218x +29.50%
2023-12-31 ILA8.13 Billion
≈ $21.79 Million
ILA1.37 Billion
≈ $3.67 Million
0.168x -7.98%
2022-12-31 ILA8.69 Billion
≈ $23.30 Million
ILA1.59 Billion
≈ $4.26 Million
0.183x +157.78%
2021-12-31 ILA11.24 Billion
≈ $30.14 Million
ILA798.00 Million
≈ $2.14 Million
0.071x -35.44%
2020-12-31 ILA11.06 Billion
≈ $29.65 Million
ILA1.22 Billion
≈ $3.26 Million
0.110x +207.80%
2019-12-31 ILA15.06 Billion
≈ $40.38 Million
ILA538.00 Million
≈ $1.44 Million
0.036x -76.94%
2018-12-31 ILA15.79 Billion
≈ $42.34 Million
ILA2.45 Billion
≈ $6.56 Million
0.155x -17.22%
2017-12-31 ILA18.75 Billion
≈ $50.25 Million
ILA3.51 Billion
≈ $9.40 Million
0.187x +25.30%
2016-12-31 ILA34.99 Billion
≈ $93.82 Million
ILA5.22 Billion
≈ $14.01 Million
0.149x -19.37%
2015-12-31 ILA29.93 Billion
≈ $80.23 Million
ILA5.54 Billion
≈ $14.86 Million
0.185x -15.64%
2014-12-31 ILA23.36 Billion
≈ $62.61 Million
ILA5.13 Billion
≈ $13.75 Million
0.220x +53.51%
2013-12-31 ILA22.64 Billion
≈ $60.69 Million
ILA3.24 Billion
≈ $8.68 Million
0.143x -28.48%
2012-12-31 ILA22.87 Billion
≈ $61.31 Million
ILA4.57 Billion
≈ $12.26 Million
0.200x +8.06%
2011-12-31 ILA22.34 Billion
≈ $59.90 Million
ILA4.13 Billion
≈ $11.08 Million
0.185x -1.57%
2010-12-31 ILA22.00 Billion
≈ $58.99 Million
ILA4.14 Billion
≈ $11.09 Million
0.188x +7.33%
2009-12-31 ILA19.26 Billion
≈ $51.63 Million
ILA3.37 Billion
≈ $9.04 Million
0.175x -11.32%
2008-12-31 ILA16.36 Billion
≈ $43.86 Million
ILA3.23 Billion
≈ $8.66 Million
0.197x +49.89%
2007-12-31 ILA13.76 Billion
≈ $36.89 Million
ILA1.81 Billion
≈ $4.86 Million
0.132x -28.44%
2006-12-31 ILA11.18 Billion
≈ $29.97 Million
ILA2.06 Billion
≈ $5.52 Million
0.184x -18.68%
2005-12-31 ILA6.05 Billion
≈ $16.22 Million
ILA1.37 Billion
≈ $3.67 Million
0.226x -2.09%
2004-12-31 ILA5.40 Billion
≈ $14.48 Million
ILA1.25 Billion
≈ $3.35 Million
0.231x +21.65%
2003-12-31 ILA3.30 Billion
≈ $8.84 Million
ILA626.60 Million
≈ $1.68 Million
0.190x -1.41%
2002-12-31 ILA1.83 Billion
≈ $4.92 Million
ILA353.70 Million
≈ $948.26K
0.193x -2.38%
2001-12-31 ILA1.38 Billion
≈ $3.71 Million
ILA273.15 Million
≈ $732.30K
0.198x +37.51%
2000-12-31 ILA1.15 Billion
≈ $3.09 Million
ILA165.63 Million
≈ $444.04K
0.144x -30.58%
1999-12-31 ILA742.30 Million
≈ $1.99 Million
ILA153.61 Million
≈ $411.82K
0.207x +94.44%
1998-12-31 ILA659.60 Million
≈ $1.77 Million
ILA70.20 Million
≈ $188.20K
0.106x -66.31%
1997-12-31 ILA612.80 Million
≈ $1.64 Million
ILA193.60 Million
≈ $519.03K
0.316x +2586.53%
1996-12-31 ILA535.20 Million
≈ $1.43 Million
ILA-6.80 Million
≈ $-18.23K
-0.013x -104.91%
1995-12-31 ILA407.60 Million
≈ $1.09 Million
ILA105.40 Million
≈ $282.57K
0.259x +131.78%
1994-12-31 ILA342.40 Million
≈ $917.96K
ILA38.20 Million
≈ $102.41K
0.112x -20.72%
1993-12-31 ILA267.90 Million
≈ $718.23K
ILA37.70 Million
≈ $101.07K
0.141x +11.33%
1992-12-31 ILA223.10 Million
≈ $598.12K
ILA28.20 Million
≈ $75.60K
0.126x +154.19%
1991-12-31 ILA183.00 Million
≈ $490.62K
ILA9.10 Million
≈ $24.40K
0.050x --

About Teva Pharmaceutical Industries Ltd

TA:TEVA Israel Drug Manufacturers - Specialty & Generic
Market Cap
$29.28 Billion
ILA10.92 Trillion ILA
Market Cap Rank
#8171 Global
#68 in Israel
Share Price
ILA9379.00
Change (1 day)
-0.56%
52-Week Range
ILA5374.00 - ILA11350.00
All Time High
ILA25447.60
About

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more